# Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy

> **NCT00627042** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 42 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** Ramucirumab (IMC-1121B)

## Key facts

- **NCT ID:** NCT00627042
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2014-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00627042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00627042, "Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00627042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*